Intelligence / Healthtech / New Clinical Trials / Amgen
Amgen
2 Nov 2026: Trial registered · Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA). Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 2 Nov 2026
- Title
- Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA)
- Conditions
- Obesity, Overweight
- Phase
- Phase 1
- Study Type
- Interventional
- Status
- Recruiting
- Countries
- United States
- Country
- United States
- Reference
- NCT07908316
- Location
- United States
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Find the decision makers at Amgen
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
Across AOS Research
Other records for Amgen in our registers.
More from United States
New Clinical Trials
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.